NCT01561664

Brief Summary

Insulin resistance is one of the main mechanisms involved in metabolic diseases. inflammation has been implicated in its pathogenesis, due to innate immunity activation by free fatty acids, lipopolysaccharides (LPS) and lactate. Free fatty acids, LPS and lactate activate innate immunity in squelettal muscle and adipose tissue via Toll-like receptor 2/4, NFkB, IRF3 (Interferon Responsive Factor 3) and cytokines secretion (TNFa, IFN g, IL1b, IL6), chemokines secretion (MCP1) and leukotrienes (LTB4). Feed back mechanisms involved in TLR signaling pathways as RLI (ribonuclease L inhibitor)/ABCE1, have never been studied in inflammation due to obesity. RLI inhibits an endoribonuclease, RNase L, which has been recently implicated in TLR signaling The purpose of this study is to analyse the role of RLI and RNase L in TLR regulation, and its potential implication in the link between obesity, inflammation and insulin resistance in adipose tissue and squeletal muscle in humans.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable obesity

Timeline
Completed

Started Nov 2011

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2011

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2011

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

March 6, 2012

Completed
17 days until next milestone

First Posted

Study publicly available on registry

March 23, 2012

Completed
1.7 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2013

Completed
Last Updated

September 18, 2015

Status Verified

March 1, 2012

Enrollment Period

Same day

First QC Date

March 6, 2012

Last Update Submit

September 17, 2015

Conditions

Keywords

obesityinsulin resistance

Outcome Measures

Primary Outcomes (1)

  • TLR regulation

    analyse the role of RLI and RNase L in TLR regulation, and its potential implication in the link between obesity, microinflammation and insulin resistance in adipose tissue and squelettal muscle in humans.

    2 years

Study Arms (3)

volunteers

ACTIVE COMPARATOR

not overweight Volunteers responding to the study criteria

Other: muscle and fat biopsy

overweight patients insulin sensitive

EXPERIMENTAL

overweight patients insulin sensitive responding to the study criteria

Other: muscle and fat biopsy

overweight insulin resistant

EXPERIMENTAL

overweight patients insulin resistant responding to the study criteria

Other: muscle and fat biopsy

Interventions

muscle and fat biopsy

overweight insulin resistantoverweight patients insulin sensitivevolunteers

Eligibility Criteria

Age50 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age between 50 and 65 years old
  • Men/ menopausal women
  • BMI \<25 kg/m2 for the control group, BMI \>30 kg/m2 for the obese group
  • Non diabetic patients
  • HOMAIR \<3 for the insulin sensitive obese group
  • Non smoking
  • Without any inflammatory disease
  • Without any first degrees relative with diabetes
  • Without any treatment that could interfere with insulin sensitivity
  • without any infection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Montpellier University Hospital

Montpellier, 34295, France

Location

MeSH Terms

Conditions

ObesityInsulin Resistance

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsHyperinsulinismGlucose Metabolism DisordersMetabolic Diseases

Study Officials

  • Jacques Mercier

    University Hospital, Montpellier

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 6, 2012

First Posted

March 23, 2012

Study Start

November 1, 2011

Primary Completion

November 1, 2011

Study Completion

December 1, 2013

Last Updated

September 18, 2015

Record last verified: 2012-03

Locations